Nutriband Inc. (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, developed using the company's AVERSA technology. The company plans to submit the name and product labeling to the U.S. Food and Drug Administration (FDA) and international regulators, as well as file for trademark protection. This product could become the first abuse-deterrent fentanyl patch designed to reduce misuse, abuse, diversion, and accidental exposure, addressing a critical public health need.
The fentanyl patch is intended for the management of pain in opioid-tolerant patients, but its high potency has led to widespread abuse and accidental overdoses. According to the press release, the potential peak annual U.S. market for an abuse-deterrent fentanyl patch is estimated at $80 million to $200 million, with additional global opportunities in pain management. The AVERSA technology can be incorporated into any transdermal patch to prevent abuse of drugs with abuse potential, making this development significant for both the company and the broader pharmaceutical industry.
Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The company's lead product under development is this abuse-deterrent fentanyl patch. The selection of a global brand name marks a key milestone in the product's commercialization pathway. The company will now focus on regulatory submissions and trademark protection to secure the brand identity worldwide.
For more details, the full press release is available at https://ibn.fm/QBBSF. Additional information about Nutriband can be found on its website at www.nutriband.com. The latest news and updates regarding NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
